Hidrogel de base nanotecnológica contendo silibinina com ação anti-inflamatória no modelo de óleo de cróton
Ano de defesa: | 2018 |
---|---|
Autor(a) principal: | |
Orientador(a): | |
Banca de defesa: | , |
Tipo de documento: | Dissertação |
Tipo de acesso: | Acesso aberto |
Idioma: | por |
Instituição de defesa: |
Universidade Federal de Santa Maria
Centro de Ciências da Saúde |
Programa de Pós-Graduação: |
Programa de Pós-Graduação em Ciências Farmacêuticas
|
Departamento: |
Análises Clínicas e Toxicológicas
|
País: |
Brasil
|
Palavras-chave em Português: | |
Palavras-chave em Inglês: | |
Área do conhecimento CNPq: | |
Link de acesso: | http://repositorio.ufsm.br/handle/1/20985 |
Resumo: | Currently, irritant contact dermatitis is the most prevalent dermatitis among the others and is triggered by the activation of innate immunity after skin contact with irritants. Silibinin (SB), a naturally occurring active, has beneficial activities for the cutaneous tissue, among which the anti-inflammatory action can be highlighted. Thus, in studies conducted in our research group, nanocapsule suspensions containing pomegranate oil as oily core and silibinin as active have been developed. Aiming at the skin application, this dissertation aimed to develop an innovative bioadhesive hydrogel for the delivery of this NC suspension and to verify its potential in the treatment of irritative contact dermatitis. The hydrogel was prepared from the polymer Pemulen® TR2, which has bioadhesive characteristics. The formulations were characterized in terms of SB content, pH, particle size and distribution, as well as spreadability and rheology, important characteristics mainly in the development of new products for dermal administration. For the studies of SB release from the hydrogels and cutaneous permeation of the active in human skin Franz cells were used. The bioadhesiveness test was performed using a texturometer and, in order to guarantee the safety of the formulations, the cutaneous biometry assay was performed, evaluating the parameters of erythema, pH, transepidermal loss of water and skin hydration. Also, considering the ability of SB to regulate inflammatory events, the viability of these hydrogels in the inflammation treatment was studied in an animal model induced by croton oil. The proposed formulations presented physico-chemical characteristics compatible with topical administration, maintaining the nanometric size after incorporation into the hydrogels (184 ± 26 nm), adequate pH range (6.70 ± 0.15), SB concentration close to concentration (0.99 ± 0.01 mg/g), as well as non-Newtonian pseudoplastic behavior. The in vitro release evidenced that the hydrogels containing the nanocapsules provided less silibinin retention in the dosage form for both media: phosphate buffer pH 5.5 plus ethanol and the buffer alone (4.73 ± 0.50 μg / mL for HP-NCSB and 1.14 ± 0.18 μg/mL for HP-SB and 2.25 ± 0.25 μg/mL from HP-NCSB and 0.49 ± 0.05 μg/mL for HP-SB, respectively). Permeation studies on human skin have indicated that the nanoencapsulation of silibinin increases its retention in the stratum corneum, which can act as a deposit for gradual release of this active. Evaluating the bioadhesive potential of the formulations, it was verified that the HP-NCSB stands out against the other formulations tested. In the in vivo study, the hydrogels containing the silibinin nanocapsules and pomegranate oil were able to act by expressively reducing ear edema and inflammatory cells. In the cutaneous biometry test, for all the parameters tested the formulations did not alter the normal skin conditions of the volunteers. Therefore, based on the results obtained, the hydrogel development was successful and the formulation has met the proposed therapeutic purpose, and may be a therapeutic alternative for the treatment of irritant contact dermatitis, using the natural source active silibinin allied to nanotechnology, since it was possible to demonstrate that the hydrogel containing silibinin nanocapsules had satisfactory results against the hydrogel containing non-nanoencapsulated silibinin, as well as it was possible to demonstrate the contribution of Pemulen® TR2 in the performance of the formulations. |
id |
UFSM-20_a155751f2a9e8efd5cd315d92f71859e |
---|---|
oai_identifier_str |
oai:repositorio.ufsm.br:1/20985 |
network_acronym_str |
UFSM-20 |
network_name_str |
Manancial - Repositório Digital da UFSM |
repository_id_str |
|
spelling |
2021-05-25T19:12:55Z2021-05-25T19:12:55Z2018-11-30http://repositorio.ufsm.br/handle/1/20985Currently, irritant contact dermatitis is the most prevalent dermatitis among the others and is triggered by the activation of innate immunity after skin contact with irritants. Silibinin (SB), a naturally occurring active, has beneficial activities for the cutaneous tissue, among which the anti-inflammatory action can be highlighted. Thus, in studies conducted in our research group, nanocapsule suspensions containing pomegranate oil as oily core and silibinin as active have been developed. Aiming at the skin application, this dissertation aimed to develop an innovative bioadhesive hydrogel for the delivery of this NC suspension and to verify its potential in the treatment of irritative contact dermatitis. The hydrogel was prepared from the polymer Pemulen® TR2, which has bioadhesive characteristics. The formulations were characterized in terms of SB content, pH, particle size and distribution, as well as spreadability and rheology, important characteristics mainly in the development of new products for dermal administration. For the studies of SB release from the hydrogels and cutaneous permeation of the active in human skin Franz cells were used. The bioadhesiveness test was performed using a texturometer and, in order to guarantee the safety of the formulations, the cutaneous biometry assay was performed, evaluating the parameters of erythema, pH, transepidermal loss of water and skin hydration. Also, considering the ability of SB to regulate inflammatory events, the viability of these hydrogels in the inflammation treatment was studied in an animal model induced by croton oil. The proposed formulations presented physico-chemical characteristics compatible with topical administration, maintaining the nanometric size after incorporation into the hydrogels (184 ± 26 nm), adequate pH range (6.70 ± 0.15), SB concentration close to concentration (0.99 ± 0.01 mg/g), as well as non-Newtonian pseudoplastic behavior. The in vitro release evidenced that the hydrogels containing the nanocapsules provided less silibinin retention in the dosage form for both media: phosphate buffer pH 5.5 plus ethanol and the buffer alone (4.73 ± 0.50 μg / mL for HP-NCSB and 1.14 ± 0.18 μg/mL for HP-SB and 2.25 ± 0.25 μg/mL from HP-NCSB and 0.49 ± 0.05 μg/mL for HP-SB, respectively). Permeation studies on human skin have indicated that the nanoencapsulation of silibinin increases its retention in the stratum corneum, which can act as a deposit for gradual release of this active. Evaluating the bioadhesive potential of the formulations, it was verified that the HP-NCSB stands out against the other formulations tested. In the in vivo study, the hydrogels containing the silibinin nanocapsules and pomegranate oil were able to act by expressively reducing ear edema and inflammatory cells. In the cutaneous biometry test, for all the parameters tested the formulations did not alter the normal skin conditions of the volunteers. Therefore, based on the results obtained, the hydrogel development was successful and the formulation has met the proposed therapeutic purpose, and may be a therapeutic alternative for the treatment of irritant contact dermatitis, using the natural source active silibinin allied to nanotechnology, since it was possible to demonstrate that the hydrogel containing silibinin nanocapsules had satisfactory results against the hydrogel containing non-nanoencapsulated silibinin, as well as it was possible to demonstrate the contribution of Pemulen® TR2 in the performance of the formulations.Atualmente, a dermatite de contato irritativa é a dermatite mais prevalente entre as demais e é desencadeada pela ativação da imunidade inata, após o contato da pele com agentes irritantes. A silibinina (SB), um ativo de ocorrência natural, apresenta atividades benéficas para o tecido cutâneo, dentre as quais pode-se destacar a ação anti-inflamatória. Desta forma, em estudos realizados no nosso grupo de pesquisa, foram desenvolvidas suspensões de nanocápsulas contendo óleo de romã como núcleo oleoso e silibinina como ativo. Visando a aplicação na pele, esta dissertação objetivou desenvolver um hidrogel bioadesivo inovador para a veiculação desta suspensão de NC e verificar seu potencial no tratamento da dermatite de contato irritativa. O hidrogel foi preparado a partir do polímero Pemulen® TR2, que apresenta características bioadesivas. As formulações foram caracterizadas quanto ao teor de SB, pH, tamanho e distribuição das partículas, bem como espalhabilidade e reologia, características importantes principalmente no desenvolvimento de novos produtos para administração cutânea. Para os estudos de liberação da SB a partir dos hidrogéis e permeação cutânea do ativo em pele humana utilizou-se células de Franz. O teste de bioadesividade foi realizado utilizando um texturômetro e, visando garantir a segurança das formulações, o ensaio de biometria cutânea foi executado, avaliando-se os parâmetros de eritema, pH, perda transepidermal de água e hidratação cutânea. Ainda, considerando a capacidade da SB em regular eventos inflamatórios, estudou-se a viabilidade destes hidrogéis no tratamento da inflamação em um modelo animal induzido por óleo de cróton. A formulação proposta apresentou características físico-químicas compatíveis com a administração tópica, mantendo o tamanho nanométrico após a incorporação nos hidrogéis (184 ± 26 nm), faixa de pH adequada (6,70 ± 0,15), concentração de SB próxima a concentração teórica (0,99±0,01 mg/g), assim como comportamento não-newtoniano pseudoplástico. A liberação in vitro evidenciou que os hidrogéis que continham as nanocápsulas proporcionaram uma menor retenção da silibinina na forma farmacêutica tanto para o meio contendo tampão fosfato pH 5,5 acrescido de etanol como para o meio apenas com tampão (4,73 ± 0,50 µg/mL para o HP-NCSB e 1,14 ± 0,18 µg/mL para o HP-SB e 2,25 ± 0,25 µg/mL a partir do HP-NCSB e 0,49 ± 0,05 µg/mL para o HP-SB, respectivamente). Os estudos de permeação em pele humana indicaram que a nanoencapsulação da silibinina aumenta sua retenção no estrato córneo, o que pode funcionar como depósito para liberação gradual deste ativo. Avaliando-se o potencial bioadesivo das formulações, constatou-se que o HP- NCSB destaca-se frente as demais formulações testadas. No estudo in vivo, os hidrogéis contendo as nanocápsulas de silibinina e óleo de romã foram capazes de atuar reduzindo expressivamente o edema de orelha e as células inflamatórias. No ensaio de biometria cutânea, para todos os parâmetros testados as formulações não alteraram as condições normais da pele dos voluntários. Portanto, baseado nos resultados obtidos, o desenvolvimento do hidrogel foi bem sucedido e que este atendeu a finalidade terapêutica proposta, podendo ser uma alternativa terapêutica para o tratamento da dermatite de contato irritativa, utilizando o ativo de origem natural silibinina aliado a nanotecnologia, uma vez que foi possível demonstrar que o hidrogel contendo nanocápsulas de silibinina teve resultados satisfatórios frente ao hidrogel contendo silibinina não-nanoencapsulada, assim como foi possível demonstrar a contribuição do Pemulen® TR2 no desempenho das formulações.porUniversidade Federal de Santa MariaCentro de Ciências da SaúdePrograma de Pós-Graduação em Ciências FarmacêuticasUFSMBrasilAnálises Clínicas e ToxicológicasAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessSemissólidosNanopartículasSilimarinaInflamaçãoSemisolidsNanoparticlesSilymarinInflammationCNPQ::CIENCIAS DA SAUDE::FARMACIAHidrogel de base nanotecnológica contendo silibinina com ação anti-inflamatória no modelo de óleo de crótonNanotechnology-based hydrogels containing silibinin with anti- inflammatory action in crotton oil modelinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisCruz, Letíciahttp://lattes.cnpq.br/3095970241017527Nogueira, Cristina WaynePaese, Karinahttp://lattes.cnpq.br/0048655224986199Rigon, Cristina400300000005600087e54fa-1802-4e8a-a314-a3ffa14190d988edf2f5-2ce3-436f-a4b2-2565a2fd22fc1e373fcc-89bd-4103-adba-676f6dcec787d4467822-0fe5-4124-912e-ddd78a6dc0fbreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSMORIGINALDIS_PPGCF_2018_RIGON_CRISTINA.pdfDIS_PPGCF_2018_RIGON_CRISTINA.pdfDissertação de Mestradoapplication/pdf2052693http://repositorio.ufsm.br/bitstream/1/20985/1/DIS_PPGCF_2018_RIGON_CRISTINA.pdfee2f5d311a17e4827e8702f40a72c60aMD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805http://repositorio.ufsm.br/bitstream/1/20985/2/license_rdf4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81956http://repositorio.ufsm.br/bitstream/1/20985/3/license.txt2f0571ecee68693bd5cd3f17c1e075dfMD53TEXTDIS_PPGCF_2018_RIGON_CRISTINA.pdf.txtDIS_PPGCF_2018_RIGON_CRISTINA.pdf.txtExtracted texttext/plain251749http://repositorio.ufsm.br/bitstream/1/20985/4/DIS_PPGCF_2018_RIGON_CRISTINA.pdf.txt57282fd1a0fa1ad21e0f4b765f9fcba5MD54THUMBNAILDIS_PPGCF_2018_RIGON_CRISTINA.pdf.jpgDIS_PPGCF_2018_RIGON_CRISTINA.pdf.jpgIM Thumbnailimage/jpeg4542http://repositorio.ufsm.br/bitstream/1/20985/5/DIS_PPGCF_2018_RIGON_CRISTINA.pdf.jpg05bff5d43768ccf0ca8648eb2a23231cMD551/209852022-10-06 17:00:34.293oai:repositorio.ufsm.br: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ório Institucionalhttp://repositorio.ufsm.br/PUBhttp://repositorio.ufsm.br/oai/requestopendoar:39132022-10-06T20:00:34Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false |
dc.title.por.fl_str_mv |
Hidrogel de base nanotecnológica contendo silibinina com ação anti-inflamatória no modelo de óleo de cróton |
dc.title.alternative.eng.fl_str_mv |
Nanotechnology-based hydrogels containing silibinin with anti- inflammatory action in crotton oil model |
title |
Hidrogel de base nanotecnológica contendo silibinina com ação anti-inflamatória no modelo de óleo de cróton |
spellingShingle |
Hidrogel de base nanotecnológica contendo silibinina com ação anti-inflamatória no modelo de óleo de cróton Rigon, Cristina Semissólidos Nanopartículas Silimarina Inflamação Semisolids Nanoparticles Silymarin Inflammation CNPQ::CIENCIAS DA SAUDE::FARMACIA |
title_short |
Hidrogel de base nanotecnológica contendo silibinina com ação anti-inflamatória no modelo de óleo de cróton |
title_full |
Hidrogel de base nanotecnológica contendo silibinina com ação anti-inflamatória no modelo de óleo de cróton |
title_fullStr |
Hidrogel de base nanotecnológica contendo silibinina com ação anti-inflamatória no modelo de óleo de cróton |
title_full_unstemmed |
Hidrogel de base nanotecnológica contendo silibinina com ação anti-inflamatória no modelo de óleo de cróton |
title_sort |
Hidrogel de base nanotecnológica contendo silibinina com ação anti-inflamatória no modelo de óleo de cróton |
author |
Rigon, Cristina |
author_facet |
Rigon, Cristina |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Cruz, Letícia |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/3095970241017527 |
dc.contributor.referee1.fl_str_mv |
Nogueira, Cristina Wayne |
dc.contributor.referee2.fl_str_mv |
Paese, Karina |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/0048655224986199 |
dc.contributor.author.fl_str_mv |
Rigon, Cristina |
contributor_str_mv |
Cruz, Letícia Nogueira, Cristina Wayne Paese, Karina |
dc.subject.por.fl_str_mv |
Semissólidos Nanopartículas Silimarina Inflamação |
topic |
Semissólidos Nanopartículas Silimarina Inflamação Semisolids Nanoparticles Silymarin Inflammation CNPQ::CIENCIAS DA SAUDE::FARMACIA |
dc.subject.eng.fl_str_mv |
Semisolids Nanoparticles Silymarin Inflammation |
dc.subject.cnpq.fl_str_mv |
CNPQ::CIENCIAS DA SAUDE::FARMACIA |
description |
Currently, irritant contact dermatitis is the most prevalent dermatitis among the others and is triggered by the activation of innate immunity after skin contact with irritants. Silibinin (SB), a naturally occurring active, has beneficial activities for the cutaneous tissue, among which the anti-inflammatory action can be highlighted. Thus, in studies conducted in our research group, nanocapsule suspensions containing pomegranate oil as oily core and silibinin as active have been developed. Aiming at the skin application, this dissertation aimed to develop an innovative bioadhesive hydrogel for the delivery of this NC suspension and to verify its potential in the treatment of irritative contact dermatitis. The hydrogel was prepared from the polymer Pemulen® TR2, which has bioadhesive characteristics. The formulations were characterized in terms of SB content, pH, particle size and distribution, as well as spreadability and rheology, important characteristics mainly in the development of new products for dermal administration. For the studies of SB release from the hydrogels and cutaneous permeation of the active in human skin Franz cells were used. The bioadhesiveness test was performed using a texturometer and, in order to guarantee the safety of the formulations, the cutaneous biometry assay was performed, evaluating the parameters of erythema, pH, transepidermal loss of water and skin hydration. Also, considering the ability of SB to regulate inflammatory events, the viability of these hydrogels in the inflammation treatment was studied in an animal model induced by croton oil. The proposed formulations presented physico-chemical characteristics compatible with topical administration, maintaining the nanometric size after incorporation into the hydrogels (184 ± 26 nm), adequate pH range (6.70 ± 0.15), SB concentration close to concentration (0.99 ± 0.01 mg/g), as well as non-Newtonian pseudoplastic behavior. The in vitro release evidenced that the hydrogels containing the nanocapsules provided less silibinin retention in the dosage form for both media: phosphate buffer pH 5.5 plus ethanol and the buffer alone (4.73 ± 0.50 μg / mL for HP-NCSB and 1.14 ± 0.18 μg/mL for HP-SB and 2.25 ± 0.25 μg/mL from HP-NCSB and 0.49 ± 0.05 μg/mL for HP-SB, respectively). Permeation studies on human skin have indicated that the nanoencapsulation of silibinin increases its retention in the stratum corneum, which can act as a deposit for gradual release of this active. Evaluating the bioadhesive potential of the formulations, it was verified that the HP-NCSB stands out against the other formulations tested. In the in vivo study, the hydrogels containing the silibinin nanocapsules and pomegranate oil were able to act by expressively reducing ear edema and inflammatory cells. In the cutaneous biometry test, for all the parameters tested the formulations did not alter the normal skin conditions of the volunteers. Therefore, based on the results obtained, the hydrogel development was successful and the formulation has met the proposed therapeutic purpose, and may be a therapeutic alternative for the treatment of irritant contact dermatitis, using the natural source active silibinin allied to nanotechnology, since it was possible to demonstrate that the hydrogel containing silibinin nanocapsules had satisfactory results against the hydrogel containing non-nanoencapsulated silibinin, as well as it was possible to demonstrate the contribution of Pemulen® TR2 in the performance of the formulations. |
publishDate |
2018 |
dc.date.issued.fl_str_mv |
2018-11-30 |
dc.date.accessioned.fl_str_mv |
2021-05-25T19:12:55Z |
dc.date.available.fl_str_mv |
2021-05-25T19:12:55Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://repositorio.ufsm.br/handle/1/20985 |
url |
http://repositorio.ufsm.br/handle/1/20985 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.cnpq.fl_str_mv |
400300000005 |
dc.relation.confidence.fl_str_mv |
600 |
dc.relation.authority.fl_str_mv |
087e54fa-1802-4e8a-a314-a3ffa14190d9 88edf2f5-2ce3-436f-a4b2-2565a2fd22fc 1e373fcc-89bd-4103-adba-676f6dcec787 d4467822-0fe5-4124-912e-ddd78a6dc0fb |
dc.rights.driver.fl_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Universidade Federal de Santa Maria Centro de Ciências da Saúde |
dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Ciências Farmacêuticas |
dc.publisher.initials.fl_str_mv |
UFSM |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
Análises Clínicas e Toxicológicas |
publisher.none.fl_str_mv |
Universidade Federal de Santa Maria Centro de Ciências da Saúde |
dc.source.none.fl_str_mv |
reponame:Manancial - Repositório Digital da UFSM instname:Universidade Federal de Santa Maria (UFSM) instacron:UFSM |
instname_str |
Universidade Federal de Santa Maria (UFSM) |
instacron_str |
UFSM |
institution |
UFSM |
reponame_str |
Manancial - Repositório Digital da UFSM |
collection |
Manancial - Repositório Digital da UFSM |
bitstream.url.fl_str_mv |
http://repositorio.ufsm.br/bitstream/1/20985/1/DIS_PPGCF_2018_RIGON_CRISTINA.pdf http://repositorio.ufsm.br/bitstream/1/20985/2/license_rdf http://repositorio.ufsm.br/bitstream/1/20985/3/license.txt http://repositorio.ufsm.br/bitstream/1/20985/4/DIS_PPGCF_2018_RIGON_CRISTINA.pdf.txt http://repositorio.ufsm.br/bitstream/1/20985/5/DIS_PPGCF_2018_RIGON_CRISTINA.pdf.jpg |
bitstream.checksum.fl_str_mv |
ee2f5d311a17e4827e8702f40a72c60a 4460e5956bc1d1639be9ae6146a50347 2f0571ecee68693bd5cd3f17c1e075df 57282fd1a0fa1ad21e0f4b765f9fcba5 05bff5d43768ccf0ca8648eb2a23231c |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM) |
repository.mail.fl_str_mv |
|
_version_ |
1794524385253523456 |